Phase 3 VX-445 triple-combination study in cystic fibrosis with F508del plus gating or residual function mutation

Phase 3, randomised, double-blind trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in percent predicted forced expiratory volume in 1 second from baseline through Week 8. Started Jan 2020; status: active, not recruiting.